tiprankstipranks
Advertisement
Advertisement
Immix Biopharma Reports Strong Interim NXC-201 Phase 2 Data
PremiumCompany AnnouncementsImmix Biopharma Reports Strong Interim NXC-201 Phase 2 Data
1M ago
Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis
Premium
The Fly
Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis
1M ago
Citizens biotechnology analyst holds analyst/industry conference call
Premium
The Fly
Citizens biotechnology analyst holds analyst/industry conference call
3M ago
Immix Biopharma Amends ATM Offering to Raise Capital
PremiumCompany AnnouncementsImmix Biopharma Amends ATM Offering to Raise Capital
3M ago
Immix Biopharma initiated with an Overweight at Morgan Stanley
Premium
The Fly
Immix Biopharma initiated with an Overweight at Morgan Stanley
3M ago
Immix Biopharma initiated with an Outperform at Citizens
Premium
The Fly
Immix Biopharma initiated with an Outperform at Citizens
4M ago
Immix Biopharma Enters Underwriting Agreement with Morgan Stanley
PremiumCompany AnnouncementsImmix Biopharma Enters Underwriting Agreement with Morgan Stanley
7M ago
Immix Biopharma Announces Positive Phase 2 Trial Results
Premium
Company Announcements
Immix Biopharma Announces Positive Phase 2 Trial Results
7M ago
Immix Biopharma 19.12M share Spot Secondary priced at $5.10
Premium
The Fly
Immix Biopharma 19.12M share Spot Secondary priced at $5.10
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100